About the SME Instrument programme, check infographics. Awarded funding for the project No “889219 -SA-VOIR” for “Assessing the feasibility of a first-in-class drug to treat glaucoma and other neurodegenerative diseases via a breakthrough mechanism-of-action”.

Glaucoma is the world’s leading cause of irreversible blindness, affecting 20 million people in Europe and the US. Known as the Alzheimer’s of the eye, glaucoma is a neurodegenerative disorder that causes deterioration in peripheral vision. We aim to develop our lead compound up to the clinical trials. In SA-VOIR, we aimed to strengthen the business case of our compound portfolio and to outline a detailed technical plan for its continued development. These documents will not only guide us in developing the drug towards Phase 1 trials in an effective and de-risked manner, it will also form critical components of our business plan.

Disclaimer: This communication reflects author’s view, EASME and EU are not responsible for any use that may be made of the information it contains.

We are delighted and proud of the support from the EU.

141, rue de la Cardonille
34396 Montpellier Cedex 5
France
[email protected]
© 2019 - MT-act - All Rights Reserved